The value of an idea lies in the using of it ~ Thomas Edison
For more than a decade now, Hemera’s team has been studying and testing therapies for the regeneration of nervous tissue.
Over the last few years, 10 independent in vivo experiments were performed on 220 mice using a model of blunt spinal cord injury, generating scientifically robust and very promising data.
In a preclinical model of severe spinal cord injury, the administration of REMAST therapy was proven to promote the repair of damaged nervous tissue and reduce the negative effects induced by a spinal cord lesion, allowing for long-lasting functional improvement.
Pre-clinical studies have shown that the therapy:
Has a neurotrophic effect, that is, it stimulates the growth of nervous tissue and motor neurons
Has an anti-inflammatory action at the site of the injury
Remodels and reduces the scar that causes disruption of neuronal connections
Has a pro-angiogenic effect, that is, it promotes the ability to create new blood vessels
REMAST therapy’s safety profile
In a preclinical experimental context, this therapy has shown a high safety profile:
Autologous approach, that is, the therapeutic cells are derived from the patient himself
No genetic manipulation, just phenotype modification
Spontaneous reversal of the activated cell phenotype a few days after the treatment
No evidence of side effects in the preclinical setting, even with long-term monitoring
Stay informed on Hemera’s latest activities with our Newsletter.